Literature DB >> 16056260

Tissue, cell and stage specificity of (epi)mutations in cancers.

Oliver M Sieber1, Simon R Tomlinson, Ian P M Tomlinson.   

Abstract

Most (epi)mutations in cancers are specific to particular tumours or occur at specific stages of development, cell differentiation or tumorigenesis. Simple molecular mechanisms, such as tissue-restricted gene expression, seem to explain these associations only in rare cases. Instead, the specificity of (epi)mutations is probably due to the selection of a restricted spectrum of genetic changes by the cellular environment. In some cases, the resulting functional defects might be constrained to be neither too strong nor too weak for tumour growth to occur; that is, they lie within a 'window' that is permissive for tumorigenesis.

Entities:  

Mesh:

Year:  2005        PMID: 16056260     DOI: 10.1038/nrc1674

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  31 in total

1.  Ionizing radiation and hematopoietic malignancies: altering the adaptive landscape.

Authors:  Courtney J Fleenor; Andriy Marusyk; James DeGregori
Journal:  Cell Cycle       Date:  2010-08-07       Impact factor: 4.534

2.  Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.

Authors:  Curtis J Henry; Andriy Marusyk; Vadym Zaberezhnyy; Biniam Adane; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Contribution of tumor heterogeneity in a new animal model of CNS tumors.

Authors:  Fuyi Chen; Albert J Becker; Joseph J LoTurco
Journal:  Mol Cancer Res       Date:  2014-02-05       Impact factor: 5.852

Review 4.  Understanding tumor heterogeneity as functional compartments--superorganisms revisited.

Authors:  Thomas G P Grunewald; Saskia M Herbst; Jürgen Heinze; Stefan Burdach
Journal:  J Transl Med       Date:  2011-05-27       Impact factor: 5.531

5.  Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer.

Authors:  Ya Zhang; Xuefeng Wu; Yan Kai; Chia-Han Lee; Fengdong Cheng; Yixuan Li; Yongbao Zhuang; Javid Ghaemmaghami; Kun-Han Chuang; Zhuo Liu; Yunxiao Meng; Meghana Keswani; Nancy R Gough; Xiaojun Wu; Wenge Zhu; Alexandros Tzatsos; Weiqun Peng; Edward Seto; Eduardo M Sotomayor; Xiaoyan Zheng
Journal:  JCI Insight       Date:  2019-12-19

6.  Generation of iPSCs from cultured human malignant cells.

Authors:  Jan E Carette; Jan Pruszak; Malini Varadarajan; Vincent A Blomen; Sumita Gokhale; Fernando D Camargo; Marius Wernig; Rudolf Jaenisch; Thijn R Brummelkamp
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

7.  Cancer as robust intrinsic state of endogenous molecular-cellular network shaped by evolution.

Authors:  Ping Ao; David Galas; Leroy Hood; Xiaomei Zhu
Journal:  Med Hypotheses       Date:  2007-09-04       Impact factor: 1.538

Review 8.  Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations.

Authors:  Andriy Marusyk; James DeGregori
Journal:  Biochim Biophys Acta       Date:  2007-10-12

Review 9.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

10.  Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study.

Authors:  Lindsay M Morton; Danielle M Karyadi; Stephen W Hartley; Megan N Frone; Joshua N Sampson; Rebecca M Howell; Joseph P Neglia; Michael A Arnold; Belynda D Hicks; Kristine Jones; Bin Zhu; Casey L Dagnall; Eric Karlins; Meredith S Yeager; Wendy M Leisenring; Yutaka Yasui; Lucie M Turcotte; Susan A Smith; Rita E Weathers; Jeremy Miller; Byron S Sigel; Diana M Merino; Amy Berrington de Gonzalez; Smita Bhatia; Leslie L Robison; Margaret A Tucker; Gregory T Armstrong; Stephen J Chanock
Journal:  JCO Precis Oncol       Date:  2020-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.